Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer

S. Argalácsová, O. Slanař, P. Vítek, P. Tesařová, H. Bakhouche, M. Dražďáková, O. Bartošová, T. Zima, L. Petruželka

. 2015 ; 64 (Suppl 4) : S539-S547.
. 2015 ; () : S539-S547.

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16031169

Recent pre-clinical evidence suggests that the active metabolite of tamoxifen, endoxifen, is a substrate for efflux pump P-glycoprotein. The aim of our study was to evaluate, if the polymoprhisms within ABCB1 gene alter tamoxifen adjuvant treatment efficacy in premenopausal women. Totally 71 premenopausal women with estrogen receptor positive breast cancer indicated for tamoxifen adjuvant treatment were followed retrospectively for median period of 56 months. The gentic polymorphisms of CYP2D6 and ABCB1 were analyzed and potential covariates as tumor grading, staging, age at the diagnosis, comedication, quantitative positivity of ER or PR were also evaluated. Cox proportional-hazards regression model indicated that patients carrying at least one variant allele in ABCB1 rs1045642 had significantly longer time to event survival compared to wild type subjects. Non-significant trend was noted for better treatment outcome of patients carrying at least one variant allele in the SNP rs2032582, while for the CYP2D6 polymorphism poor metabolizer phenotype resulted in worse outcome in comparison to extensive metabolizers subjects with HR of 4.04 (95 % CI 0.31-52.19). Similarly, patients using CYP2D6 inhibitors had non-significantly shorter time-to-event as compared to never users resulting in hazard ratio of 2.06 (95 % CI 0.40-10.63). ABCB1 polymorphisms may affect outcome of tamoxifen adjuvant treatment in premenopausal breast cancer patiens. This factor should be taken into account in addition to the CYP2D6 polymorphism or phenotypic inhibition of CYP2D6 activity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16031169
003      
CZ-PrNML
005      
20241120093208.0
007      
ta
008      
161101s2015 xr d f 000 0|ENG||
009      
AR
024    7_
$a 10.33549/physiolres.933234 $2 doi
035    __
$a (PubMed)26681084
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a ENG
044    __
$a xr
100    1_
$a Argalácsová, Soňa $u Department of Oncology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic; Institute of Pharmacology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic $7 xx0144657
245    10
$a Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer / $c S. Argalácsová, O. Slanař, P. Vítek, P. Tesařová, H. Bakhouche, M. Dražďáková, O. Bartošová, T. Zima, L. Petruželka
520    9_
$a Recent pre-clinical evidence suggests that the active metabolite of tamoxifen, endoxifen, is a substrate for efflux pump P-glycoprotein. The aim of our study was to evaluate, if the polymoprhisms within ABCB1 gene alter tamoxifen adjuvant treatment efficacy in premenopausal women. Totally 71 premenopausal women with estrogen receptor positive breast cancer indicated for tamoxifen adjuvant treatment were followed retrospectively for median period of 56 months. The gentic polymorphisms of CYP2D6 and ABCB1 were analyzed and potential covariates as tumor grading, staging, age at the diagnosis, comedication, quantitative positivity of ER or PR were also evaluated. Cox proportional-hazards regression model indicated that patients carrying at least one variant allele in ABCB1 rs1045642 had significantly longer time to event survival compared to wild type subjects. Non-significant trend was noted for better treatment outcome of patients carrying at least one variant allele in the SNP rs2032582, while for the CYP2D6 polymorphism poor metabolizer phenotype resulted in worse outcome in comparison to extensive metabolizers subjects with HR of 4.04 (95 % CI 0.31-52.19). Similarly, patients using CYP2D6 inhibitors had non-significantly shorter time-to-event as compared to never users resulting in hazard ratio of 2.06 (95 % CI 0.40-10.63). ABCB1 polymorphisms may affect outcome of tamoxifen adjuvant treatment in premenopausal breast cancer patiens. This factor should be taken into account in addition to the CYP2D6 polymorphism or phenotypic inhibition of CYP2D6 activity.
650    _2
$a dospělí $7 D000328
650    _2
$a hormonální protinádorové látky $x aplikace a dávkování $7 D018931
650    _2
$a nádory prsu $x farmakoterapie $x genetika $7 D001943
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a cytochrom P-450 CYP2D6 $x genetika $7 D019389
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a P-glykoproteiny $x genetika $7 D018435
650    _2
$a premenopauza $x účinky léků $x genetika $7 D017697
650    _2
$a tamoxifen $x aplikace a dávkování $7 D013629
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Slanař, Ondřej $7 xx0058262 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic; Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Vítek, Pavel, $d 1960- $7 mzk2006322806 $u Institute of Radiotherapy, First Faculty of Medicine, Charles University and Hospital Na Bulovce, Prague, Czech Republic
700    1_
$a Tesařová, Petra, $d 1961- $7 xx0102804 $u Department of Oncology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Bakhouche, Hana $7 xx0324719 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Dražďáková, Marcela $7 xx0075797 $u Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Bartošová, Olga $7 mzk2016928814 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Zima, Tomáš, $d 1966- $7 jn20000620440 $u Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Petruželka, Luboš, $d 1952- $7 jn19990209650 $u Department of Oncology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 64, Suppl 4 (2015), s. S539-S547
773    0_
$t Prof. Jaroslav Květina celebrates his 85th birthday $g (2015), s. S539-S547 $w MED00191412
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20161101 $b ABA008
991    __
$a 20241120093203 $b ABA008
999    __
$a ok $b bmc $g 1173609 $s 955827
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 64 $c Suppl 4 $d S539-S547 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
BMC    ##
$a 2015 $d S539-S547 $m Prof. Jaroslav Květina celebrates his 85th birthday $x MED00191412
LZP    __
$b NLK118 $a Pubmed-20161101

Find record

Citation metrics

Archiving options